Roivant Sciences Ltd. ROIV

Roivant Sciences jumped ~17% after mid-stage results for mosliciguat in PH-ILD, triggering a Phase 3 program as enrollment in the PHrontier study begins. In the Phase 2 PHocus trial (n=135), mosliciguat reduced pulmonary vascular resistance by 56.3% vs placebo (p<0.0001), and improved six-minute walk distance by 35.2 meters (p=0.0027). NT-proBNP fell 53.2% (p=0.0002). Week 24 exploratory data showed persistent gains (52.7m 6MWD, 75.9% NT-proBNP reduction). The drug was well tolerated, with cough slightly lower than placebo. Roivant has Lisraya approved in adults with dermatomyositis, and JPM estimated up to $1.5B risk-adjusted peak sales for mosliciguat; Phase 3 PHrontier aims to confirm results in a larger trial. The readout also notes potential expansion to other indications, though outcomes remain uncertain and market competition exists. Positive Phase 2 results for mosliciguat and move to Phase 3, along with potential large peak sales and Lisraya context, could materially boost Roivant's pipeline value and investor sentiment despite clinical and competitive risks.

Roivant Sciences' subsidiary Immunovant will discontinue development of IMVT-1402 (imeroprubart) for cutaneous lupus erythematosus after a Phase II proof-of-concept trial failed to meet the primary endpoint, CLASI-A score at Week 12 in 57 adults. Although numerical trends favored the drug on several endpoints and greater IgG reductions correlated with better responses, Immunovant cited the results and competitive landscape as reasons to end CLE development. Safety and tolerability were consistent with prior studies. Immunovant will continue developing IMVT-1402 in Graves' disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, CIDP, and Sjögren's disease, with timelines for other programs remaining on track. The decision does not affect other indications or the broader Roivant pipeline. Stopping a CLE program reduces Roivant's near-term pipeline value and could weigh on sentiment, even as other IMVT-1402 indications proceed.

Roivant and Immunovant announced topline results from Period 1 of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE). The primary endpoint, percent change from baseline in CLASI-A at Week 12, was not statistically significant. Numerical trends favored IMVT-1402 across several endpoints, and deeper IgG reductions correlated with improved responses, but Immunovant will stop CLE development due to the results and competitive landscape. IMVT-1402 maintained a favorable safety/tolerability profile. All other clinical development timelines remain on track. Immunovant will continue pursuing IMVT-1402 in other autoimmune diseases, including Graves' disease, difficult-to-treat RA, myasthenia gravis, CIDP, and Sjogren's disease. The randomized, double-blind trial enrolled 57 adults (NCT06980805) for 12 weeks in Period 1. CLE failure reduces near-term upside for IMVT-1402, but other Roivant assets and timelines remain unaffected.

Roivant Sciences is moving from clinical development to commercialization. Stifel initiated Buy with a $51 target, implying ~29% upside. The firm projects about $9B in ownership-adjusted sales by 2037 if its multi-asset strategy succeeds, led by Lisraya (brepocitinib). Lisraya was approved Aug 27 for adults with dermatomyositis and is being evaluated in non-infectious uveitis (Phase 3 topline in H2 2026), cutaneous sarcoidosis, and lichen planopilaris. The approval will test Roivant’s ability to translate clinical success into revenue, with uptake depending on physician awareness, reimbursement, and competition in rare diseases. Beyond Lisraya, IMVT-1402 (anti-FcRn) is in several autoimmune indications with 2026 updates and potential registrational trials; mosliciguat showed positive Phase 2 in pulmonary hypertension with ILD and is moving to Phase 3. Roivant had about $3.9B in cash as of June 30, and Moderna settlement boosted cash via Genevant/Arbutus. Hedge funds raised exposure, but short interest remains elevated. Lisraya approval and a $9B sales potential by 2037, plus key pipeline milestones, could materially affect Roivant's growth trajectory.

Roivant Sciences reports positive PH ILD trial data that signals progress in its pulmonary hypertension treatment program for interstitial lung disease. Positive PH ILD trial results strengthen Roivant's clinical pipeline and can materially lift future revenue potential.

Roivant Sciences Ltd. (ROIV) achieves pulmonary hypertension breakthrough with strong potential to accelerate company growth trajectory. Pulmonary hypertension breakthrough positions Roivant for accelerated growth in core therapeutic area.

Roivant Sciences Ltd. (ROIV) stock surged after its lung disease drug met all clinical trial goals. Positive lung disease drug trial success drives sharp stock gains and strengthens future growth outlook.

Roivant stock surges on robust data from rare lung disease candidate. Robust data from rare lung disease candidate boosts Roivant stock and alters company trajectory.

Roivant’s experimental lung disease drug met its key Phase 2 goal, sending ROIV shares to all-time highs. Positive Phase 2 trial result strengthens drug pipeline value and supports higher valuation.

Roivant Sciences shares rose after positive Phase 2 results for Mosliciguat. Positive Phase 2 Mosliciguat data lifted shares and signals material pipeline progress for Roivant.

Roivant Sciences' Pulmovant reports positive Phase 2 results for Mosliciguat in PH-ILD. Positive Phase 2 data for Mosliciguat advances Roivant's pulmonary pipeline and lifts valuation prospects.

Roivant Sciences reported positive PHocus study results for Mosliciguat in PH-ILD patients and announced its ongoing Phase 3 PHrontier study. Positive PHocus results for Mosliciguat plus Phase 3 PHrontier initiation strengthen pipeline and long-term prospects.

Pulmovant announces positive PHocus study results for Mosliciguat in PH-ILD patients and reveals ongoing Phase 3 PHrontier study. Positive PHocus results plus Phase 3 start for Mosliciguat advance Roivant's key pulmonary pipeline asset.

Roivant (ROIV) stock hits all-time high as Q2 hedge fund holdings surge 41%. Higher hedge fund ownership signals stronger institutional interest that may lift near-term sentiment and price.

Lisraya’s $35,000 monthly price could affect Roivant Sciences Ltd. (ROIV) market position and performance. Lisraya pricing at $35,000 monthly signals major competitive pressure likely to shift Roivant trajectory and investor views.

Roivant Sciences Ltd. gains approval for the first oral dermatomyositis drug, prompting assessment of the market opportunity size. First-in-class oral drug approval expands Roivant's pipeline and opens new revenue stream in dermatomyositis.

Roivant to present topline results from Phase 2 PHocus Study of Mosliciguat in PH-ILD patients at ERS Congress 2026 on September 8, 2026, and host investor call. Phase 2 trial data release for key pipeline asset can moderately shift valuation and sentiment.

Roivant Sciences Ltd. (ROIV) secures FDA approval for LISRAYA in Dermatomyositis and launches the product immediately. FDA approval for LISRAYA enables immediate market entry and potential revenue surge for Roivant Sciences Ltd. (ROIV).

Roivant Sciences Ltd. received FDA approval for LISRAYA (brepocitinib) to treat adults with dermatomyositis and the drug is now available in the U.S. FDA approval and U.S. launch of new drug LISRAYA for dermatomyositis creates major revenue stream and strategic expansion for Roivant.

Priovant, tied to Roivant Sciences, secured FDA approval for LISRAYA (brepocitinib) treating adults with dermatomyositis and launched the drug for immediate U.S. availability. FDA approval and U.S. launch of brepocitinib adds a major approved asset that can drive revenue and shift Roivant's trajectory.

JAMA Dermatology published skin-specific outcomes from Roivant Sciences' Phase 3 VALOR Trial of Brepocitinib in Dermatomyositis. Phase 3 trial data publication in dermatomyositis adds clinical validation to Brepocitinib and may lift near-term sentiment around Roivant's pipeline.

Roivant Sciences Ltd. released first quarter results, leading to questions on whether the stock is overvalued based on financial performance and market valuation metrics. First quarter results and related valuation questions can moderately influence near-term investor sentiment and trading activity.

Roivant Sciences Ltd. (ROIV) held its Q1 2026 earnings call covering quarterly financial results, pipeline updates, and operational outlook. Quarterly earnings call delivers financial results and guidance that can shift near-term investor views but rarely transforms long-term company trajectory.

Roivant Sciences Q1 earnings call highlights quarterly financial results, operational updates, and strategic outlook for the company. Q1 earnings call details directly inform quarterly performance metrics and near-term guidance.

Roivant Sciences Ltd reported Q1 2026 earnings call highlights covering strategic advances and strong performance. Strategic advances noted in earnings call point to moderate effects on financial performance and market positioning.

Roivant Sciences Ltd. (ROIV) released financial results for the first quarter ended June 30, 2026, and issued a business update. Quarterly earnings releases and business updates typically produce moderate effects on near-term stock movement and sentiment without altering long-term strategy.

Priovant enrolls first patients in Phase 3 BEACON+ study of brepocitinib for cutaneous sarcoidosis. Phase 3 enrollment marks pipeline progress with limited near-term effect on financials or market position.

Immunovant released corporate updates and financial results for the quarter ended June 30, 2026. Quarterly results from Immunovant may moderately affect ROIV investor sentiment and valuation.

Roivant Sciences Ltd. (ROIV) conducted its Q4 2025 earnings call covering financial results, operational updates and forward guidance. Earnings call delivers financial metrics and strategic outlook that directly influence stock valuation and investor positioning.

Roivant Sciences Ltd. swung to profits, driving its shares up 15%. Profit swing triggers immediate 15% share price gain and lifts near-term sentiment.